Table 3.
Variables Influencing HIV Decay
| Variable | Estimate (95% CI) | P Value |
|---|---|---|
| Parametric coefficients | ||
| Intercept | 2.12 (1.8 to 2.43) | <.0001 |
| Infant sex | 0.004 (−.28 to .29) | .98 |
| Blipsa | 0.12 (−.31 to .55) | .6 |
| Documented cART nonadherenceb | −0.08 (−.22 to .06) | .3 |
| PoC tested | 0.16 (−.34 to .66) | .5 |
| Approximate significance of smooth terms | EDF | P Value |
| cART duration, d | 3.19 | <.0001 |
| Infant age at cART initiation, d | 1.00 | .80 |
| Infant age suppressed, wk | 1.00 | .0003 |
| Plasma viral load, log10 HIV RNA copies/mL over time | 1.00 | <.0001 |
| CD4 percentage over time | 2.02 | .3 |
Generalized additive mixed model adjusted R2 = 0.86.
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; EDF, effective degrees of freedom; HIV, human immunodeficiency virus; PoC, point-of-care tested.
aA blip was defined as one plasma viral load >100 HIV RNA copies/mL preceded and followed by an undetectable plasma viral load, or a plasma viral load that increased <1 log10 HIV RNA copies/mL between consecutive monthly measurements during initial viremia decline.
bEvidence or reports of missing ≥2 doses.